Cargando…

Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer

Bispecific T cell engagers (BiTEs) represent a promising immunotherapy, but their efficacy against immunologically cold tumors such as pancreatic ductal adenocarcinoma remains unclear. Oncolytic viruses (OVs) can transform the immunosuppressive tumor microenvironment into the active state and also s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shiyu, Li, Fan, Deng, Li, Ma, Qiongqiong, Lu, Wenyi, Zhao, Zhuoqian, Liu, Huanzhen, Zhou, Yixuan, Hu, Manli, Wang, Hui, Yan, Yingbin, Zhao, Mingfeng, Zhang, Hongkai, Du, Mingjuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493249/ https://www.ncbi.nlm.nih.gov/pubmed/37701851 http://dx.doi.org/10.1016/j.omto.2023.08.011

Ejemplares similares

OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment
por: Liu, Shiyu, et al.
Publicado: (2023)

CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model
por: Wang, Ruikun, et al.
Publicado: (2022)

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
por: Gao, Jing, et al.
Publicado: (2023)

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
por: Yano, Hiroshi, et al.
Publicado: (2014)

IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
por: Shi, Hongtai, et al.
Publicado: (2023)

Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
por: Arnold, A., et al.
Publicado: (2020)

Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas
por: Klempner, S.J., et al.
Publicado: (2023)

FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer
por: Liu, Yifan, et al.
Publicado: (2023)

Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer
por: Xu, Bo, et al.
Publicado: (2022)

The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Antitumor Efficacy of Oncolytic Herpes Virus Type 1 Armed with GM-CSF in Murine Uveal Melanoma Xenografts
por: Liu, Sisi, et al.
Publicado: (2020)

Potent antitumor efficacy of human dental pulp stem cells armed with YSCH-01 oncolytic adenovirus
por: He, Xu, et al.
Publicado: (2023)

Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer
por: Zhang, Jianwei, et al.
Publicado: (2020)

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
por: Cao, Weijie, et al.
Publicado: (2022)

Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
por: Bähr-Mahmud, Hayat, et al.
Publicado: (2023)

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
por: Wang, Xi, et al.
Publicado: (2022)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
por: Qi, Changsong, et al.
Publicado: (2023)

Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
por: Singh, Prabhsimranjot, et al.
Publicado: (2017)

Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis
por: Ungureanu, Bogdan Silviu, et al.
Publicado: (2021)

Development and comparison of (68)Ga/(18)F/(64)Cu-labeled nanobody tracers probing Claudin18.2
por: Wei, Weijun, et al.
Publicado: (2022)

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
por: Qi, Changsong, et al.
Publicado: (2022)

CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy
por: Liu, Zuqiang, et al.
Publicado: (2015)

Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies
por: Moentenich, Valeska, et al.
Publicado: (2020)

Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer
por: Kim, Hyung-Don, et al.
Publicado: (2023)

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy
por: Liang, Jie, et al.
Publicado: (2021)

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
por: Park, Jeong A, et al.
Publicado: (2023)

MiRNA-182-5p aggravates experimental ulcerative colitis via sponging Claudin-2
por: Tang, Siwen, et al.
Publicado: (2021)

Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers
por: Zhong, Weixiang, et al.
Publicado: (2022)

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
por: Kubota, Y., et al.
Publicado: (2023)

Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity
por: Xie, Jun, et al.
Publicado: (2023)

Disruption of Claudin-1 Expression by miRNA-182 Alters the Susceptibility to Viral Infectivity in HCV Cell Models
por: Riad, Sarah E., et al.
Publicado: (2018)

Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma
por: Rohde, Christoph, et al.
Publicado: (2019)

Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
por: Kowalsky, Stacy J., et al.
Publicado: (2018)

IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity
por: Yang, Min, et al.
Publicado: (2021)

Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

Updates to the antitumor mechanism of oncolytic virus
por: Bai, Yang, et al.
Publicado: (2019)

Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
por: Tang, Jing, et al.
Publicado: (2022)

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
por: Freedman, Joshua D, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dab9tlssqde0o6qbg5tu7tf3ts